Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

Advances in Enzyme Regulation

Volumn 48, Issue 1, 2008, Pages 113-135

  McCubrey, James A ^a   Sokolosky, Melissa L ^a   Lehmann, Brian D ^a   Taylor, Jackson R ^a   Navolanic, Patrick M ^a   Chappell, William H ^a   Abrams, Stephen L ^a   Stadelman, Kristin M ^a   Wong, Ellis W T ^a   Misaghian, Negin ^a   Horn, Stefan ^b   Bäsecke, Jörg ^b   Libra, Massimo ^c   Stivala, Franca ^c   Ligresti, Giovanni ^d   Tafuri, Agostino ^e   Milella, Michele ^f   Zarzycki, Marek ^g   Dzugaj, Andrzej ^g   Chiarini, Francesca ^h   Evangelisti, Camilla ^h   Martelli, Alberto M ^h   Terrian, David M ^a   Franklin, Richard A ^a   Steelman, Linda S ^a   more..

^a EAST CAROLINA UNIVERSITY   (United States)

^b Division of Hematology/Oncology   (Germany)

^c UNIVERSITY OF CATANIA   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY OF WROC AW   (Poland)

^h UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE; PROTEIN KINASE B; PTEN PROTEIN, HUMAN; RAF PROTEIN;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL AGING; CELL CYCLE; CELL TRANSFORMATION; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL AGING; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RAF KINASES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

MAMMALIA;

EID: 51349105331     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2008.02.006     Document Type: Article

References (202)

1. Adachi T., Kar S., Wang M., and Carr B.I. Transient and sustained ERK phosphorylation and nuclear translocation in growth control. J Cell Physiol 192 (2002) 151-159
2. Allan L.A., Morrice N., Brady S., Magee G., Pathak S., and Clarke P.R. Inhibition of caspase-9 by phosphorylation at Thr125 by ERK MAP kinase. Nat Cell Biol 5 (2003) 647-654
3. Aplin A.E., Stewart S.A., Assoian R.K., and Juliano R.L. Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. J Cell Biol 153 (2001) 273-282
4. Arcinas M., Heckman C.A., Mehew J.W., and Boxer L.M. Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma. Cancer Res 61 (2001) 5202-5206
5. Bader A.G., Kang S., Zhao L., and Vogt P.K. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5 (2005) 921-929
6. Barnes G., Bulusu V.R., Hardwick R.H., Carroll N., Hatcher H., Earl H.M., et al. A review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivec™). Int J Surg 3 (2005) 206-212
7. Blagosklonny M.V. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16 (2002) 455-462
8. Blalock W.L., Navolanic P.M., Steelman L.S., Shelton J.G., Moye P.W., Lee J.T., et al. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. Leukemia 17 (2003) 1058-1067
9. Blalock W.L., Weinstein-Oppenheimer C., Chang F., Hoyle P.E., Wang X.-Y., Algate P.A., et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia 13 (1999) 1109-1166
10. Brooks S.C., Locke E.R., and Soule H.D. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 1248 (1973) 6251-6253
11. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96 (1999) 857-868
12. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
13. Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., Hostetter G., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448 (2007) 439-444
14. Carter B.Z., Milella M., Tsao T., McQueen T., Schober W.D., Hu W., et al. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 17 (2003) 2081-2089
15. Centers for Disease Control and Prevention. Cancer: symptoms of breast cancer (2006), Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/cancer/breast/basic_info/symptoms.htm
16. Chang F., Lee J.T., Navolanic P.M., Steelman L.S., Shelton J.G., Blalock W.L., et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17 (2003) 590-603
17. Chang F., Steelman L.S., Shelton J.G., Lee J.T., Navolanic P.N., Blalock W.L., et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol 22 (2003) 469-480
18. Clark A.S., West K., Streicher S., and Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1 (2002) 707-717
19. Cocco L., Follo M.Y., Faenza I., Bavelloni A., Billi A.M., Martelli A.M., et al. Nuclear inositide signaling: an appraisal of phospholipase C beta1 behavior in myeloblastic and leukemia cells. Adv Enzyme Regul 47 (2007) 2-9
20. Coutant A., Rescan C., Gilot D., Loyer P., Guguen-Guillouzo C., and Baffet G. PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival. Hepatology 36 (2002) 1079-1088
21. Damen J.E., Liu L., Rosten P., Humphries R.K., Jefferson A.B., Majerus P.W., et al. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triposphate 5-phosphatase. Proc Natl Acad Sci U S A 93 (1996) 1689-1693
22. Dan H.C., Sun M., Naneko S., Feldman R.I., Nicosia S.V., Wang H.G., et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279 (2004) 5405-5412
23. Davis R.J. Transcriptional regulation by MAP kinases. Mol Reprod Dev 4 (1995) 459-467
24. Davis R.J., Derijard B., Raingeaud J., Barrett T., Wu I.H., Han J., et al. Independent human MAP kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267 (1995) 682-685
25. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351 (2000) 95-105
26. DeGraffenried L.A., Fulcher L., Friedrichs W.E., Grunwald V., Ray R.B., Hidalgo M., et al. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 15 (2004) 1510-1516
27. Delaney A.M., Printon J.A., Chen H., Faumann E.B., and Dudley D.T. Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mol Cell Biol 22 (2002) 7593-7602
28. Deng T., and Karin M. c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature 371 (1994) 171-175
29. Deng X., Kornblau S.M., Ruvolo P.P., and May Jr. W.S. Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. J Natl Cancer Inst Monogr 28 (2001) 30-37
30. Deng X., Xiao L., Lang W., Gao F., Ruvolo P., and May Jr. W.S. Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem 276 (2001) 23681-23688
31. Devarajan E., Sahin A.A., Chen J.S., Krishnamurthy R.R., Aggarwal N., Brun A.M., et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 21 (2002) 8843-8851
32. KIP1. Mol Cell Biol 20 (2000) 9138-9148
33. Domina A.M., Vrana J., Gregory M.A., Hann S.R., and Craig R.W. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23 (2004) 5301-5315
34. Drexler H.G. Expression of the FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 10 (1996) 588-599
35. Du K., and Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273 (1998) 32377-32379
36. Dufner A., Anjelkovic M., Burgering B.M.T., Hemmings B., and Thomas G. Protein kinase B localization and activation and eukaryotic translational initiation factor 4E-binding protein phosphorylation. Mol Cell Biol 19 (1999) 4525-4534
37. Eblen S.T., Catling A.D., Assanah M.C., and Weber M.J. Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2. Mol Cell Biol 21 (2001) 249-259
38. Edinger A.L., and Thompson C.B. An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival. Oncogene 23 (2004) 5654-5663
39. Elmore L.W., Xu D., Dumur C., Holt S.E., and Gewirtz D.A. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response. Clin Cancer Res. 11 (2005) 2637-2643
40. Engleman J.A., Luo J., and Canley L.C. The evolution phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7 (2006) 606-619
41. Enmark E., Pelto-Huikko M., Grandien K., Lagercrantz S., Lagercrantz J., Fried G., et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82 (1997) 4258-4265
42. Evangelisti C., Bortul R., Falà F., Tabellini G., Goto K., and Martelli A.M. Nuclear diacylglycerol kinases: emerging downstream regulators in cell signaling networks. Histol Histopathol 22 (2007) 573-579
43. Fasco M.J., Keyomarsi K., Arcaro K.F., and Gierthy J.F. Expression of an estrogen receptor alpha variant protein in cell lines and tumors. Mol Cell Endocrinol 166 (2000) 156-169
44. Feilotter H.E., Coulon V., McVeigh J.L., Boag A.H., Dorion-Bonnet F., Duboue B., et al. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 79 (1999) 718-723
45. Fingar D.C., and Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23 (2004) 3151-3171
46. Flotho S., Valcamonica S., Mach-Pascual G., Schmahl L., Corral J., Ritterbach H., et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 13 (1999) 32-37
47. Fry T.J., and Mackall C.L. Interleukin-7: from bench to clinic. Blood 99 (2002) 3892-3904
48. Fu Z., Aronoff-Spencer E., Wu H., Gerfen G.J., and Backer J.M. The iSH2 domain of PI 3-kinase is a rigid tether for p110 and not a conformational switch. Arch Biochem Biophys 432 (2004) 244-251
49. Fuqua S.A., Schiff R., Parra I., Friedrichs W.E., Su J.L., McKee D.D., et al. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 59 (1999) 5425-5428
50. Gao T., Furnari F., and Newton A.C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18 (2005) 13-24
51. Garcia J.M., Silva J., Pena C., Garcia V., Rodriguez R., Cruz M.A., et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 41 (2004) 117-124
52. Gardai S.J., Whitlock B.B., Xiao Y.Q., Bratton D.B., and Henson P.M. Oxidants inhibit ERK/MAPK and prevent its ability to delay neutrophil apoptosis downstream of mitochondrial changes and at the level of XIAP. J Biol Chem 279 (2004) 44695-44703
53. Giles F.J., and Albitar M. Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med 5 (2005) 653-661
54. Gottlieb T.M., Leal J.F., Seger R., Taya Y., and Oren M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 21 (2002) 1299-1303
55. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., et al. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007) 153-158
56. Hall-Jackson C.A., Eyers P.A., Cohen P., Goedert M., Boyle F.T., Hewitt N., et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 6 (1999) 559-568
57. Harada H., Andersen J.S., Mann M., Terada N., and Korsmeyer S.J. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci U S A 98 (2001) 9666-9670
58. Harada H., Quearry B., Ruiz-Vela A., and Korsmeyer S.J. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci U S A 101 (2004) 15313-15317
59. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8 (2005) 179-183
60. Heimbrook D.C., Huber H.E., Stirdivant S.M., Claremon D., Liverton N., Patrick D.R., et al. Identification of potent, selective kinase inhibitors of Raf. Proc Am Assoc Cancer Res Ann Meet 39 (1998) 558
61. Hochhaus A., McCubrey J.A., and Killmann N.M.B. Spotlight Imatinib: a model for signal transduction inhibitors. Leukemia 16 (2002) 1205-1206
62. Hollestelle A., Elstrodt F., Nagel J.H.A., and Kallemeijn W.W. Phosphatidylinositol-3-OH kinase or Ras pathway mutations in human breast cancer cell lines. Mol Cancer Res 5 (2007) 195-201
63. Howe C.J., LaHair M.M., McCubrey J.A., and Franklin R.A. Redox regulation of the CaM-kinases. J Biol Chem 279 (2004) 44573-44581
64. Howe C.J., LaHair M.M., Maxwell J.A., Lee J.T., Robinson P.J., Rodriguezz-Mora O., et al. Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced Ikappa B phosphorylation in human T lymphocytes. J Biol Chem 277 (2002) 30469-30476
65. Hresko R.C., and Mueckler M. mTOR·RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280 (2005) 40406-40416
66. Hu M.C., Lee D.F., Xia W., Golfman L.S., Ou-Yang F., Yang J.Y., et al. IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117 (2004) 225-237
67. Iijima Y., Laser M., Shiraishi H., Willey C.D., Sundaravadivel B., Xu L., et al. c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J Biol Chem 277 (2002) 23065-23075
68. Inhorn R.C., Carlesso N., Durstin M., Frank D.A., Griffin J.D., Inhorn R.C., et al. Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750. Proc Natl Acad Sci U S A 92 (1995) 8665-8669
69. Jemal A., Tiwar R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics. CA Cancer J Clin 54 (2004) 829
70. Jia W., Yu C., Rahmani M., Krystal G., Sausville E.A., Dent P., et al. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood 102 (2003) 1824-1832
71. Jin J., and Woodgett J.R. Chronic activation of protein kinase Bbeta/Akt2 leads to multinucleation and cell fusion in human epithelial kidney cells: events associated with tumorigenesis. Oncogene 18 (2005) 5459-5470
72. Jonassen A.K., Mjos O.D., and Sack M.N. p70S6 kinase is a functional target of insulin activated Akt cell-survival. Biochem Biophys Res Commun 315 (2004) 160-165
73. Kang S., Bader A.G., Zhao L., and Vogt P.K. Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle 4 (2005) 578-581
74. Karin M., Minden A., Lin A., McMahon M., Lange-Carter C., Derijard B., et al. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 266 (1994) 1719-1723
75. Kavanaugh W.M., Pot D.A., Chin S.M., Deuter-Reinhard M., Jefferson A.B., Norris F.A., et al. Multiple forms of an inositol polyphosphate 5-phosphatase form signaling complexes with Shc and Grb2. Curr Biol 6 (1996) 438-445
76. Kirkegaard T., Witton C.J., McGlynn L.M., Tovey S., Dunne B., Lyon A., et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207 (2005) 139-146
77. Konecny G.E., Pegram M.D., Venkatesan N., Finn R., Yang G., Rahmeh M., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66 (2006) 1630-1639
78. Kornblau S.M., Womble M., Qiu Y.H., Jackson C.E., Chen W., Konopleva M., et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108 (2006) 2358-2365
79. Lanfrancone L., Pelicci G., Brizzi M.F., Aronica M.G., Casciari C., Giuli S., et al. Overexpression of Shc proteins potentiates the proliferative response to the granulocyte-macrophage colony-stimulating factor and recruitment of Grb2/Sos and Grb2/p140 complexes to the beta receptor subunit. Oncogene 10 (1995) 907-917
80. Lange-Carter C.A., and Johnson G.L. Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science 265 (1994) 1458-1461
81. Lawlor M.A., and Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. J Cell Sci 114 (2001) 2903-2910
82. Liaw D., Marsh D.J., Li J., Dahia P.L.M., Wang S.I., Zheng Z., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16 (1997) 64-67
83. Lee Jr. J.T., and McCubrey J.A. Targeting the Raf kinase cascade in cancer therapy - novel molecular targets and therapeutic strategies. Expert Opin Ther Targets 6 (2002) 659-678
84. Lee Jr. J.T., and McCubrey J.A. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention. Leukemia 16 (2002) 486-507
85. Lehmann B.D., McCubrey J.A., Jefferson H.S., Paine M.S., Chappell W.H., and Terrian D.M. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 6 (2007) 595-605
86. Leslie N.R., Gray A., Pass I., Orchiston E.A., and Downes C.P. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signaling pathways downstream of phosphoinositide 3-kinase. Biochem J 346 (2000) 827-833
87. Lespagnard L., Gancberg D., Maaroufi Y., Leclercq G., Larsimont D., and Verhest A. In situ amplification of oestrogen receptor alpha mRNA in breast cancer cell lines and tumours. Mol Pathol 54 (2001) 197-199
88. Ley R., Balmanno K., Hadfield K., Weston C., and Cook S.J. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278 (2003) 18811-18816
89. Leygue E., Dotzlaw H., Watson P.H., and Murphy L.C. Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res 59 (1999) 1175-1179
90. Li D.M., and Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57 (1997) 2124-2129
91. Li J., Simpson L., Takahashi M., Miliaresis C., Myers M.P., Tonks N., et al. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 58 (1998) 5667-5672
92. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
93. Liang Y., Yan C., and Schor N.F. Apoptosis in the absence of caspase 3. Oncogene 20 (2001) 6570-6578
94. Lioubin M.N., Algate P.A., Tsai S., Carlberg K., Aebersold A., and Rohrschneider L.R. P150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity. Genes Develop 10 (1996) 1084-1095
95. Lu Y., Lin Y.Z., LaPushin R., Cuevas B., Fang X., Yu S.X., et al. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18 (1999) 7034-7045
96. Luo Y., Shoemaker A.R., Liu X., Woods K.W., Thomas S.A., deJong R., et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 4 (2005) 977-986
97. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Bannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cancer to gefitinib. New Engl J Med 350 (2004) 2129-2139
98. Lyons J.F., Wilhelm S., Hibner B., and Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8 (2001) 219-225
99. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., and Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121 (2005) 179-193
100. Madrid L.V., Wang C.Y., Guttridge D.C., Schottelius A.J., Baldwin A.S., and Mayo M.W. Akt suppresses apoptosis by stimulating the transactivation potential of the Rel A/p65 subunit of NF-kappaB. Mol Cell Biol 20 (2000) 1626-1638
101. Mahalingam M., and Templeton D. Constitutive activation of S6 kinase by deletion of amino-terminal autoinhibitory and rapamycin sensitivity domains. Mol Cell Biol 16 (1996) 405-413
102. Mahimainathan L., and Choudhury G.G. Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem 279 (2004) 15258-15268
103. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., and Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol Cell 10 (2002) 151-162
104. Marais R., Light Y., Paterson H.F., and Marshall C.J. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J 14 (1995) 3136-3145
105. Marais R., Light Y., Paterson H.F., Mason C.S., and Marshall C.J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic Ras and tyrosine kinases. J Biol Chem 272 (1997) 4378-4383
106. Marani M., Hancock D., Lopes R., Tenev T., Downward J., and Lemoine N.R. Role of Bim in the survival pathway induced by Raf in epithelial cells. Oncogene 23 (2004) 2431-2441
107. Martelli A.M., Faenza I., Billi A.M., Manzoli L., Evangelisti C., Fala F., et al. Intranuclear 3′-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis?. Cell Signal 18 (2006) 1101-1107
108. Martelli A.M., Tazzari P.L., Evangelisti C., Chiarini F., Blalock W.L., Billi A.M., et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 14 (2007) 2009-2023
109. Martin D.E., Soulard A., and Hall M.N. TOR regulates ribosomal protein gene expression via PKA and the Forkhead transcription factor FHL1. Cell 119 (2004) 969-979
110. Mason C.S., Springer C.J., Cooper R.G., Superti-Furga G., Marshall C.J., and Marais R. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 18 (1999) 2137-2148
111. Matsuguchi T., Salgia R., Hallek M., Eder M., Druker B., Ernst T.J., et al. Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem 269 (1994) 5016-5021
112. Mayo M.W., and Baldwin A.S. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochem Biophys Acta 1470 (2000) M55-M62
113. Mayo L.D., and Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 98 (2001) 11598-11603
114. Mazzucchelli C., Vantaggiato C., Ciamei A., Fasano S., Pakhotin P., Krezel W., et al. Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron 34 (2002) 807-820
115. McCubrey J.A., Lee J.T., Steelman L.S., Blalock W.L., Moye P.W., Chang F., et al. Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Detect. Prevent 25 (2005) 375-393
116. McCubrey J.A., May W.S., Duronio V., and Mufson A. Serine/threonine phosphorylation in cytokine signal transduction. Leukemia 14 (2000) 9-21
117. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773 (2007) 1263-1284
118. kip1. Nature 404 (2000) 782-787
119. Mobasheri A., Richardson S., Mobasheri R., Shakibaei M., and Hoyland J.A. Hypoxia inducible factor-1 and facilitative glucose transporters GLUT1 and GLUT3: putative molecular components of the oxygen and glucose sensing apparatus in articular chondrocytes. Histol Histopathol 20 (2005) 1327-1338
120. Mukherjee R., Bartlett J.M.S., Krishna N.S., Underwood M.A., and Edwards J. Raf-1 expression may influence progression to androgen insensitive prostate cancer. The Prostate 64 (2005) 101-107
121. Muraille E., Pesesse X., Kuntz C., and Erneux C. Distribution of the src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement in SHIP-2 in negative signaling of B-cells. Biochem J 342 (1999) 697-705
122. Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H., et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A 94 (1997) 9052-9057
123. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 (2004) 117-127
124. Nakae J., Park B.C., and Accili D. Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem 274 (1999) 15982-15985
125. Navolanic P.M., Steelman L.S., and McCubrey J.A. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int J Oncol 22 (2003) 237-252
126. Nimwegen M.J., Huigsloot H., Camier A., Tijdens I.B., and van de Water B. Focal adhesion kinase and protein kinase B cooperate to suppress doxorubicin-induced apoptosis of breast tumor cells. Mol Phamacol 70 (2006) 1330-1339
127. Noguchi M., Ropars V., Roumestand C., and Suizu F. Proto-oncogene TCL1: more than just a coactivator for Akt. FASEB J 21 (2007) 1-12
128. Obexer P., Geiger K., Ambros P.F., Meister B., and Ausseriechner M.J. FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ 14 (2007) 534-547
129. Ohren J.F., Chen H., Pavlovsky A., Whitehead C., Zhang E., Kuffa P., et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11 (2004) 1192-1197
130. Okuda K., Foster R., and Griffin J.D. Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor. Ann NY Acad Sci 872 (1999) 305-313
131. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.L.M., and Donner D.B. NF-kappaB activation by tumor necrosis factor requires the Akt serine-threonine kinase. Nature 401 (1999) 82-85
132. Panwalkar A., Verstovsek S., and Giles F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100 (2004) 657-666
133. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor mutations are common in lung cancers from "never smokers" are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101 (2004) 13306-13311
134. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2 (2005) 57-61
135. Persad S., and Dedhar S. The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metastasis Rev 22 (2003) 375-384
136. del Peso L., Gonzalez-Garcia M., Page C., Herrera R., and Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278 (1997) 687-689
137. Ponti C., Gibellini D., Boin F., Melloni E., Manzoli F.A., Cocco L., et al. Role of CREB transcription factor in c-fos activation in natural killer cells. Eur J Immunol 32 (2002) 3358-3365
138. Poola I., Abraham J., and Baldwin K. Identification of ten exon deleted ERbeta mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor beta mRNA is distinct from that of estrogen receptor alpha. FEBS Lett 516 (2002) 133-138
139. Poola I., Koduri S., Chatra S., and Clarke R. Identification of twenty alternatively spliced estrogen receptor alpha mRNAs in breast cancer cell lines and tumors using splice targeted primer approach. J Steroid Biochem Mol Biol 72 5 (2000) 249-258
140. Qi X.J., Wildey G.M., and Howe P.H. Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem 281 (2006) 813-823
141. Raftopoulou M., Etienne-Manneville S., Self A., Nicholls S., and Hall A. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science 303 (2004) 1179-1181
142. Rao P., and Mufson R.A. A membrane proximal domain of the human interleukin-3 receptor beta c subunit that signals DNA synthesis in NIH 3T3 cells specifically binds a complex of Src and Janus family tyrosine kinases and phosphatidylinositol 3-kinase. J Biol Chem 270 (1995) 6886-6893
143. Rhei E., Kang L., Bogomolniy F., Federici M.G., Borgen P.I., and Boyd J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57 (1997) 3657-3659
144. Robinson M.J., Stippec S.A., Goldsmith E., White M.A., and Cobb M.H. A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr Biol 8 (1998) 1141-1150
145. Rodriguez-Viciana P., Warne P.H., Dhand R., Vanhaesebroeck B., Gout I., Fry M.J., et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370 (1994) 527-532
146. Romanelli A., Martin K.A., Toker A., and Bleinis J. p70 S6 Kinase is regulated by protein kinase Cζ and participates in a phosphoinositide 3-kinase-regulated signaling complex. Mol Cell Biol 19 (1999) 2921-2928
147. Romashkova J.A., and Makarov S.S. NF-kappaB is a target of Akt in anti-apoptotic PDGF signaling. Nature 401 (1999) 86-90
148. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 554
149. Scheid M.P., and Duronio V. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proc Natl Acad Sci U S A 95 (1998) 7439-7444
150. Sequist L.V., Haber D.A., and Lynch T.J. Epidermal growth factor receptor mutations in non-small cell lung cancer; predicting clinical response to kinase inhibitors. Clin Cancer Res 11 (2005) 5668-5670
151. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature 441 (2006) 424-430
152. Shelton J.G., Steelman L.S., Lee J.T., Knapp S.L., Blalock W.L., Moye P.W., et al. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene 22 (2003) 2478-2492
153. Shelton J.G., Moye P.W., Steelman L.S., Blalock W.L., Lee J.T., Franklin R.A., et al. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 17 (2003) 1765-1782
154. Shelton J.G., Steelman L.S., Abrams S.L., Bertrand F.E., Franklin R.A., McMahon M., et al. The epidermal growth factor receptor as a target for therapeutic intervention in numerous cancers-What's genetics got to do with it?. Expert Opin Ther Targets 9 (2005) 1009-1030
155. Shelton J.G., Steelman L.S., Abrams S.L., White E.R., Akula S.M., Franklin R.A., et al. Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle 4 (2005) 822-830
156. Shen W.H., Balajee A.S., Wang J., Wu H., Eng C., Pandolfi P.P., et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128 (2007) 157-170
157. Shimada A., Taki T., Tabuchi K., Tawa A., Horibe K., Tsuchida M., et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8:21): a study of the Japanese Childhood AML. Cooperative Study Group. Blood 107 (2006) 1806-1809
158. Shishodia S., and Aggarwal B.B. Nuclear factor-κB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer. Cancer Treat Res 119 (2004) 139-173
159. Singh B., Ittmann M.M., and Krolewski J.J. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosome Cancer 21 (1998) 166-171
160. Songyang Z., Baltimore D., Cantley L.C., Kaplan D.R., and Franke T.F. Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci U S A 94 (1997) 11345-11350
161. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
162. Soule H.D., Vazguez J., Long A., Albert S., and Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51 (1973) 1409-1416
163. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15 (1997) 356-362
164. Steelman L.S., Bertrand F.E., and McCubrey J.A. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets 8 (2004) 537-550
165. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., and McCubrey J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18 (2004) 189-218
166. Stirewalt D.L., Kopecky K.J., Meshinchi S., Appelbaum F.R., Slovak M.L., Willman C.L., et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97 (2001) 3589-3595
167. Tai Y.T., Fulciniti M., Hideshima T., Song W., Leiba M., Li X.F., et al. Inhibition of ERK1/2 activity by the EMR1/2 inhibitor AZD6244 (ARRY-142886) induces human multiple myeloma cell apoptosis in the bone marrow microenvironment: a new therapeutic strategy for MM. Blood 108 (2006) 3463
168. Tamburini J., Elie C., Bardet V., Chapuis N., Park S., Broët P., et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 110 (2007) 1025-1028
169. Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., and Yamada K.M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280 (1998) 1614-1617
170. Tauchi T., Boswell H.S., Leibowitz D., Broxmeyer H.E., Tauchi T., Boswell H.S., et al. Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med 179 (1994) 167-175
171. Taylor V., Wong M., Brandts C., Reilly L., Dean N.M., Cowsert L.M., et al. 5′ Phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol Cell Biol 20 (2000) 6860-6871
172. Thomas R.S., Tymms M.J., McKinlay L.H., Shannon M.F., Seth A., and Kola I. ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Oncogene 23 (1997) 2845-2855
173. Tokunaga E., Kimura Y., Mashino K., Oki E., Kataoka A., Ohno S., et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 13 (2006) 137-144
174. Tokunaga C., Yoshino K., and Yonezawa K. mTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun 313 (2004) 443-446
175. Tortora G., Bianco R., Daniele G., Ciardiello F., McCubrey J.A., Ricciardi M.R., et al. Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumors and hematological malignancies. Drug Resist Updates 10 (2007) 81-100
176. Tresini M., Lorenzini A., Frisoni L., Allen R.G., and Cristofalo V.J. Lack of Elk-1 phosphorylation and dysregulation of the extracellular regulated kinase signaling pathway in senescent human fibroblast. Exp Cell Res 269 (2001) 287-300
177. Troppmair J., and Rapp U.R. Raf and the road to cell survival: a tale of bad spells, ring bearers and detours. Biochem Pharmacol 66 (2003) 1341-1345
178. Trotman L.C., Wang X., Alimonti A., Chen Z., Teruya-Feldstein J., Yang H., et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128 (2007) 141-156
179. Troussard A.A., Mawji N.M., Ong C., Mui A., St-Arnaud R., and Dedhar S. Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem 278 (2003) 22374-22378
180. Tsutsui S., Inoue H., Yasuda K., Suzuki K., Higashi H., Era S., et al. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 68 (2005) 398-404
181. Twiddy D., Cohen G.M., MacFarlane M., and Cain K. Casape-7 is directly activated by the ∼700-kDa apoptosome complex and is released as a stable XIAP-caspase-7 ∼200-kDa complex. J Biol Chem 281 (2006) 3876-3888
182. Vogt P.K., Bader A.G., and Kang S. Phosphoinositide 3-kinase: from viral oncoprotein to drug target. Virology 344 (2006) 131-138
183. Wang C.Y., Bassuk A.G., Boise L.H., Thompson C.B., Bravo R., and Leiden J.M. Activation of the granulocyte-macrophage colony-stimulating factor promoter in T cells requires cooperative binding of Elf-1 and AP-1 transcription factors. Mol Cell Biol 14 (1994) 1153-1159
184. Wang D., Boerner S.A., Winkler J.D., and LoRusso P.M. Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 1773 (2007) 1248-1255
185. Wang L.H., Chan J.L.K., and Li W. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells. Int J Cancer 121 (2007) 2911-2918
186. Wang J.M., Chao J.R., Chen W., Kuo M.L., Yen J.J., and Yang-Yen H.F. The antiapoptotic gene mcl-1 is upregulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol 19 (1999) 6195-6206
187. Weber M.J., and Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 91 (2004) 13-25
188. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004) 332-337
189. Weng L.P., Brown J.L., and Eng C. PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet 10 (2001) 599-604
190. Weng L.P., Smith W.M., Dahia P.L., Ziebold U., Gil E., Lees J.A., et al. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res 59 (1999) 5808-5814
191. Weston C.R., Balmanno K., Chalmers C., Hadfield K., Molton S.A., Ley R., et al. Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene 22 (2003) 1281-1293
192. Witzig T.E., and Kaufmann S.H. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 7 (2006) 285-294
193. Xing J., Ginty D.D., and Greenberg M.E. Coupling of the Ras-MAPK pathway to gene activation by Rsk2, a growth factor regulated CREB kinase. Science 273 (1996) 959-963
194. Xu S., Robbins D., Frost J., Dang A., Lange-Carter C., and Cobb M.H. MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase. Proc Natl Acad Sci U S A 92 (1995) 6808-6812
195. Xu Z., Ma D.Z., Wang L.Y., Su J.M., and Zha X.L. Transforming growth factor-beta1 stimulated protein kinase B serine-473 and focal adhesion kinase tyrosine phosphorylation dependent on cell adhesion in human hepatocellular carcinoma SMMC-7721 cells. Biochim Biophys Res Commun 312 (2003) 388-396
196. Yeh T.C., Marsh V., Bernat B.A., Ballard J., Colwell H., Evans R.J., et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13 (2007) 1576-1583
197. Yoshida T., Eguchi H., Nakachi K., Tanimoto K., Higashi Y., Suemasu K., et al. Distinct mechanisms of loss of estrogen receptor alpha gene expression in human breast cancer: Methylation of the gene and alteration of trans-acting factors. Carcinogenesis 21 (2000) 2193-2201
198. You H., Pellegrini M., Tsuchihara K., Yamamoto K., Hacker G., Erlacher M., et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med 203 (2006) 1657-1663
199. Yu C., Mao X., and Li W.X. Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway. Biochem Biophys Res Commun 331 (2005) 391-397
200. Yu J., Wjasow C., and Backer J.M. Regulation of the p85/p110alpha phosphatidylinositol 3′-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains. J Biol Chem 273 (1996) 30199-30203
201. Zhang Y., Gao X., Saucedo L.J., Ru B., Edgar B.A., and Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5 (2003) 578-581
202. Zhou B.P., and Hung M.C. Novel targets of Akt, p21(Cip1.WAF1), and MDM2. Semin Oncol 29 (2002) 62-70